Navigation Links
Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30, 2013, on Tuesday, November 12, 2013 prior to market open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36014873.

The following day, Orexigen management will present a company overview at the Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation is scheduled for Wednesday, November 13th at 9:30 a.m. Mountain Time.  

The webcasts of the live and subsequently archived conference call and conference presentation can be accessed on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following each event.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
3. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
4. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
5. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
10. Orexigen Therapeutics to Present at Upcoming Investor Conferences
11. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... of cartilage, cellular, bone, skin and soft-tissue allografts ... to advance patient healing, today announced that AlloWrap® ... been moved to the high-cost reimbursement category. ... reach doctors and their patients," said Kimberly ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of the "United States ... report to their offering.      (Logo: ... adhesives in the United States ... 2020 Medical device manufacturers across ...
(Date:5/28/2015)... 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO ... Martell , to the position of Executive Chairman. Mr. ... Board of Directors. In this new role, he will ... refine and execute on the strategic plan to transition ... for orphan oncology indications with high unmet medical need. ...
Breaking Medicine Technology:AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5
... From today, an innovative non-drug, non-invasive treatment ... all hypertensive patients on NHS prescription. RESPeRATE is an ... When used for just 15 minutes a day, at ... significant, all-day blood pressure reduction beyond that seen with ...
... Therapeutics, Inc. (NASDAQ: HALO ) today presented ... tolerability study of HTI-501 (an investigational, conditionally active recombinant ... International Academy of Cosmetic Dermatology in Cancun, Mexico. Data ... portion of the clinical trial. The Phase 1/2 trial ...
Cached Medicine Technology:NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 2NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 3NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 4HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:5/28/2015)... MA (PRWEB) May 28, 2015 Workers’ compensation ... the typical state, a recent study by the Workers ... falling over a three-year period. , The WCRI study, ... in which workers missed seven days or more of work ... months, the average 2011 Michigan claim was 4 percent lower ...
(Date:5/28/2015)... Ticket Down is a reputable source of presale tickets ... Argentina in early September. , Two of the best ... pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico and Argentina ... Tuesday, September 8th at 9 p.m. The match will feature ... some of the most loved players in the entire sport. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 According ... ( http://www.idataresearch.com ), the shoulder reconstruction device market, ... small bone & joint market in 2014. This ... arthroplasty procedures in the U.S. due to increased ... device technology resulting in greater patient outcomes. Therefore, ...
(Date:5/28/2015)... The connected car is gaining more traction with ... have some iteration of a connected offering in the ... companies as the data collected can be used to ... (UBI). This is the primary reason that 800+ senior ... Conference & Exhibition. , Andrew Pym, TU Automotive’s ...
(Date:5/28/2015)... lifeIMAGE announced today that it ... by Cambia Health Solutions (Portland, Ore.), a ... care by creating a person-focused and economically sustainable system. ... exchanging medical imaging, will use this financing to expand ... of its network capabilities and implement the next phases ...
Breaking Medicine News(10 mins):Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
... million in the latest round of National Health and ... ever NHMRC funding amount for the greatest number of ... health and medical research grants today. , Monash University ... 62 individual projects, including: , $1.8 million ...
... Satyam Computer,Services Ltd. (NYSE: SAY ), a ... reported US GAAP results for its second,quarter, which ... Despite a challenging market that impacted several key ... exceeded its guidance in,the second quarter. Revenue was ...
... Health Message to Austin,s American,Heart Association Heart Walk, ... was the leading,cause of death among Texans in ... People with heart disease are at an increased ... flu. Therefore, the,U.S. Centers for Disease Control and ...
... Kicks Off Regional Expansion With Mobile Healthy,Living Experience ... World of Grains brand announced today,their expansion ... brand,will host a Mobile Healthy Living Experience at ... of making simple, better decisions,to improve their lifestyle ...
... Services; Kathleen A. Walsh named VP, Product Management; Gilbert ... for team to commercialize and support initial ... of NewCardio,s platform technology, SANTA CLARA, Calif., Oct. 17 ... services company, today,announced the hiring of three key executives to ...
... Cohera Medical Inc. today announced,it has secured $16.1 ... ongoing,development of TissuGlu(R), a novel surgical adhesive for ... led by Bradford Capital Partners, included,participation from existing ... financing provides the company with sufficient capital to ...
Cached Medicine News:Health News:Monash wins $32m for health and medical research 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 3Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 4Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 5Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 6Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 7Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 8Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 9Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 10Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 3Health News:NewCardio Announces New Client Services Team 2Health News:NewCardio Announces New Client Services Team 3Health News:NewCardio Announces New Client Services Team 4Health News:Cohera Medical Secures $16.1 Million in Series B Financing 2
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
Medicine Products: